Coerente Capital Management Has $17.78 Million Holdings in Pfizer Inc. $PFE

Coerente Capital Management raised its holdings in Pfizer Inc. (NYSE:PFE) by 5.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 697,710 shares of the biopharmaceutical company’s stock after acquiring an additional 37,096 shares during the period. Pfizer comprises 3.2% of Coerente Capital Management’s holdings, making the stock its 16th biggest holding. Coerente Capital Management’s holdings in Pfizer were worth $17,778,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Norges Bank bought a new position in Pfizer in the 2nd quarter valued at approximately $2,270,157,000. Vanguard Group Inc. grew its stake in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Pfizer by 75.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after acquiring an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Bank of America cut their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Finally, Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $27.88.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Significant GLP‑1 activity: Pfizer is pursuing GLP‑1 obesity opportunities and recently struck a China licensing deal, which investors view as a potential growth catalyst beyond legacy products. This Could Be Key to Pfizer’s Turnaround in 2026
• Positive Sentiment: Oncology collaboration: Pfizer entered a multi‑year discovery collaboration with Cartography Biosciences to identify tumor‑selective antigens, expanding its immuno‑oncology pipeline potential. Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
• Neutral Sentiment: Vaccine study update: Pfizer provided an update on a Scottish observational study of its RSV maternal vaccine — progress that is worth monitoring but not immediately market moving until clinical readouts or regulatory steps. Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch
• Neutral Sentiment: Drug price changes: Reports say Pfizer plans price increases on many medicines starting Jan. 1 — a potential near‑term revenue tailwind but also a regulatory and political risk. Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals
• Neutral Sentiment: Exchange query on Pfizer Limited: A regional exchange sought clarification from Pfizer Limited on past financials — relevant for the local unit but unlikely to materially affect NYSE‑listed PFE unless escalated. Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results
• Negative Sentiment: Litigation risk: A Multi‑District Litigation over Depo‑Provera has set its first trial for December 2026 after an FDA label change; more than 2,100 plaintiffs are involved — an ongoing legal overhang for PFE. Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio
• Negative Sentiment: Analyst caution: UBS initiated a Hold citing patent‑cliff concerns and an uncertain pipeline, limiting upside expectations and pressuring sentiment toward a conservative valuation. Patent Cliff Overhang and Uncertain Pipeline Offset Obesity Upside, Justifying Hold on Fairly Valued Pfizer Shares
• Negative Sentiment: Earnings / guidance pressure: Previews and analysis flag a likely revenue decline and continued margin pressure in 2026, and investors are parsing mixed quarterly results (EPS beat but revenue miss) and FY guidance for signs of sustained growth. Pfizer’s Quarterly Earnings Preview: What You Need to Know

Pfizer Stock Down 0.7%

Pfizer stock opened at $25.26 on Thursday. The firm has a market cap of $143.61 billion, a price-to-earnings ratio of 14.68 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a 50 day moving average price of $25.23 and a two-hundred day moving average price of $24.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.